Trial Profile
A phase II randomised trial investigating cetuximab as as a single agent and in combination with irinotecan in patients with EGFR-expressing metastatic colorectal cancer who were refractory to irinotecan-based chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- 22 Jan 2016 New trial record